Prediction of the Treatment Response and Local Failure of Patients With Brain Metastasis Treated With Stereotactic Radiosurgery Using Machine Learning: A Systematic Review and Meta-Analysis Publisher Pubmed



Habibi MA¹ ; Rashidi F² ; Habibzadeh A³ ; Mehrtabar E⁴ ; Arshadi MR⁴ ; Mirjani MS⁵ Show Affiliations
Source: Neurosurgical Review Published:2024

Abstract

Background: Stereotactic radiosurgery (SRS) effectively treats brain metastases. It can provide local control, symptom relief, and improved survival rates, but it poses challenges in selecting optimal candidates, determining dose and fractionation, monitoring for toxicity, and integrating with other modalities. Practical tools to predict patient outcomes are also needed. Machine learning (ML) is currently used to predict treatment outcomes. We aim to investigate the accuracy of ML in predicting treatment response and local failure of brain metastasis treated with SRS. Methods: PubMed, Scopus, Web of Science (WoS), and Embase were searched until April 16th, which was repeated on October 17th, 2023 to find possible relevant papers. The study preparation adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. The statistical analysis was performed by the MIDAS package of STATA v.17. Results: A total of 17 articles were reviewed, of which seven and eleven were related to the clinical use of ML in predicting local failure and treatment response. The ML algorithms showed sensitivity and specificity of 0.89 (95% CI: 0.84–0.93) and 0.87 (95% CI: 0.81–0.92) for predicting treatment response. The positive likelihood ratio was 7.1 (95% CI: 4.5–11.1), the negative likelihood ratio was 0.13 (95% CI: 0.08–0.19), and the diagnostic odds ratio was 56 (95% CI: 25–125). Moreover, the pooled estimates for sensitivity and specificity of ML algorithms for predicting local failure were 0.93 (95% CI: 0.76–0.98) and 0.80 (95% CI: 0.53–0.94). The positive likelihood ratio was 4.7 (95% CI: 1.6–14.0), the negative likelihood ratio was 0.09 (95% CI: 0.02–0.39), and the diagnostic odds ratio was 53 (95% CI: 5-606). Conclusion: ML holds promise in predicting treatment response and local failure in brain metastasis patients receiving SRS. However, further studies and improvements in the treatment process can refine the models and effectively integrate them into clinical practice. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.